- Lung cancer therapy including novel compounds and early phase trials
- Breast cancer therapeutics including novel compounds and early phase trials
- Health services research
- Economics of lung cancer therapy
- Treatment decision-making in advanced cancer, including development of patient decision aids
- Patient-physician communication
Rationale and Protocol for a Canadian Multicenter Phase II Randomized Trial Assessing Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-small-cell Lung Cancer (NCT02788461).
Clin Lung Cancer. 2018 May 16;:
Oncotarget. 2018 Apr 27;9(32):22559-22570
Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors.
CNS Drugs. 2018 May 24;:
Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.
Lung Cancer. 2018 Jun;120:142-148
CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study.
Ann Oncol. 2017 Nov 01;28(suppl_10):
Cancer Treat Rev. 2018 Feb 22;65:65-77
J Thorac Oncol. 2018 Mar 10;:
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
J Clin Oncol. 2018 Feb 14;:JCO2017776385
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy.
ESMO Open. 2016;1(6):e000118
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Associate Professor, Department of Medicine, University of Toronto
President, Lung Cancer Canada
Chair, Working Group on Economic Analysis, National Cancer Institute of Canada Clinical Trials Group